- Conditions: Squamous Cell Carcinoma; Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; University of Pittsburgh
Not yet recruiting - verified May 2012 - Conditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Cyclophosphamide; Drug: Cetuximab
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: MEHD7945A; Drug: cetuximab
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Drug: nab-paclitaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Chemoradiation; Radiation: Chemoradiation; Procedure: Quality-of-life assessment
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012 - Condition: Advanced Cancers
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Valproic Acid; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Drug: Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: MLN8237; Drug: Cetuximab; Radiation: Radiotherapy
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012 - Condition: Colorectal Cancer
Intervention: Drug: Panitumumab and bortezomib
Sponsors: Georgetown University; Georgetown University; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011 - Condition: Squamous Cell Carcinoma Of The Head And Neck
Interventions: Drug: Cetuximab; Drug: Dasatinib
Sponsors: University of Pittsburgh; University of Pittsburgh; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Biological: recombinant interleukin-12; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Esophageal Cancer; Neoplasms, Esophageal
Interventions: Drug: Everolimus; Drug: Paclitaxel; Drug: carboplatin; Drug: cetuximab
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Squamous Cell Head and Neck Cancer; Non-small Cell Lung Cancer; Triple Negative Breast Cancer; Other Tumors With EGFR Dependence
Interventions: Drug: MM-121 (SAR256212); Drug: Irinotecan; Drug: Cetuximab
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Cisplatin; Drug: Carboplatin; Drug: Cetuximab; Drug: Taxane
Sponsors: Stanford University; Stanford University; Varian Medical Systems
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: Cetuximab; Drug: Carboplatin
Sponsors: Stanford University; Stanford University
Recruiting - verified October 2011 - Condition: Advanced Cancers
Interventions: Device: SIR-Spheres; Drug: Cetuximab; Drug: Erlotinib; Procedure: Break-Through Scan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012 - Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)Condition: Head and Neck Cancer
Interventions: Drug: Cetuximab; Drug: OSI-906; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Not yet recruiting - verified February 2012 - Conditions: Colorectal Cancer; Dermatologic Complications; Lung Cancer; Therapy-related Toxicity
Interventions: Biological: cetuximab; Biological: panitumumab; Drug: erlotinib hydrochloride; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Colorectal Cancer; Cancer of Pancreas; Pancreatic Neoplasm; Malignant Neoplasm of Large Intestine; Malignant Tumor of Colon; Colon Carcinoma; Cancer of Colon; Pancreatic Cancer
Interventions: Drug: FOLFOX6; Biological: EGFRBi armed ATC Infusions
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified September 2011 - Condition: Head and Neck Cancer
Interventions: Drug: Cetuximab; Drug: Nab-paclitaxel; Drug: Carboplatin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Celgene Corporation
Recruiting - verified February 2012 - Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Biological: Sym004
Sponsors: Symphogen A/S; Symphogen A/S
Recruiting - verified February 2012 - Conditions: Colorectal Carcinoma; CRC
Interventions: Biological: JX-594; Drug: Irinotecan
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics; Transgene
Recruiting - verified January 2012 - Conditions: Dermatologic Complications; Malignant Neoplasm; Pain
Interventions: Drug: menadione topical lotion; Other: placebo; Other: questionnaire administration; Procedure: management of therapy complications
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2012 - Condition: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: E7050; Drug: Cetuximab
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: RO5083945; Drug: FOLFIRI; Drug: cetuximab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Head and Neck Squamous Cell Cancer
Intervention: Drug: Cetuximab
Sponsors: Louisiana State University Health Sciences Center Shreveport; Louisiana State University Health Sciences Center Shreveport
Recruiting - verified April 2012 - Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Drug: TLR8 agonist VTX-2337; Biological: cetuximab; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: flow cytometry; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Biological: cetuximab; Drug: paclitaxel; Drug: carboplatin; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Procedure: biopsy
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified April 2012 - Conditions: Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; KRAS Protein, Human
Interventions: Drug: AUY922; Drug: Cetuximab
Sponsors: Swedish Medical Center; Swedish Medical Center; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Colonic Neoplasms; Cancer of the Colon; Colon Cancer; Colon Neoplasms; Colonic Cancer
Interventions: Drug: Cetuximab; Drug: AZD6244
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Head and Neck Neoplasms; Cancer of the Head and Neck
Intervention: Drug: Carboplatin, cetuximab and RAD001
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified November 2011 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: irinotecan hydrochloride; Biological: bevacizumab; Biological: cetuximab; Drug: capecitabine; Genetic: mutation analysis; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: nucleic acid sequencing; Genetic: protein expression analysis; Genetic: polymerase chain reaction; Genetic: DNA analysis
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Lung Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Bevacizumab; Drug: Cetuximab; Drug: Cixutumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eli Lilly and Company; Genentech; ImClone LLC
Recruiting - verified May 2012 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified February 2011 - Conditions: Colorectal Cancer; Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab; Drug: Cetuximab; Drug: PX-866 and cetuximab; Drug: Cetuximab
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified April 2012 - Conditions: Glioblastoma Multiforme (GBM); ANAPLASTIC ASTROCYTOMA (AOA)
Intervention: Drug: Superselective Intraarterial Cerebral Infusion of Cetuximab
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Ridaforolimus
Sponsors: Brown University; Debora G. Isdale; Rhode Island Hospital; The Miriam Hospital; Memorial Hospital of Rhode Island; Roger Williams Medical Center
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: RO4929097; Drug: cetuximab
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Colorectal Cancer; Lung Cancer; Head and Neck Cancer
Intervention: Drug: cetuximab and lapatinib
Sponsors: Georgetown University; Georgetown University; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Cetuximab; Drug: Cetuximab; Drug: Docetaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Radiotherapy (RT); Other: Chemotherapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Squamous Cell Carcinoma
Intervention: Drug: Cetuximab and Lenalidomide
Sponsors: University of Chicago; University of Chicago; Celgene Corporation
Recruiting - verified June 2011 - Condition: Head and Neck Cancer
Interventions: Drug: Everolimus escalating dose; Drug: Everolimus or Placebo
Sponsors: University of Chicago; University of Chicago; Novartis Pharmaceuticals
Recruiting - verified June 2011 - Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Cetuximab and stereotactic radiosurgery
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified August 2011 - Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: Cetuximab; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System; Bristol-Myers Squibb
Recruiting - verified June 2011 - Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Carboplatin; Drug: Cisplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified October 2011 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: BIBW 2992 plus cetuximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Carboplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified March 2012 - Conditions: Thymoma; Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: temsirolimus; Drug: cisplatin; Drug: cetuximab
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified March 2012 - Condition: Brain Cancer
Intervention: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Children's Healthcare of Atlanta; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; Phoenix Children's Hospital; Alberta Children's Hospital; University of Colorado, Denver; Seattle Children's Hospital; Johns Hopkins University; Children's Mercy Hospital-Kansas City, MO; MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab (Erbitux); Drug: Panitumumab (Vectibix)
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Conditions: Liver Cancer; Advanced Cancer
Interventions: Drug: Irinotecan; Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Head and Neck Cancer
Intervention: Other: bevacizumab, cisplatin, cetuximab, radiation therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech
Recruiting - verified January 2012 - Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Cetuximab; Drug: IMC-A12; Procedure: Surgical tumor resection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; ImClone LLC
Recruiting - verified February 2012 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Advanced Cancers
Interventions: Drug: HAI Oxaliplatin; Drug: 5-FU; Drug: Bevacizumab; Drug: Cetuximab; Drug: Leucovorin; Drug: 5-FU; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Advanced Cancer
Interventions: Drug: Sirolimus; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Head and Neck Cancer; Neoplasm Metastasis
Interventions: Drug: BMS-754807; Drug: cetuximab (Erbitux®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Carcinoma, Squamous Cell
Intervention: Biological: EGFR Antisense DNA
Sponsors: University of Pittsburgh; University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Advanced Cancers
Intervention: Drug: Erlotinib Hydrochloride (Tarceva)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Advanced Cancers
Interventions: Drug: Erlotinib; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: Cetuximab; Drug: Dasatinib; Drug: Cisplatin; Radiation: Radiation Therapy
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Bristol-Myers Squibb
Recruiting - verified August 2011 - Condition: Pancreatic Cancer
Intervention: Drug: irinotecan, oxaliplatin and cetuximab
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Metastatic Cancer
Interventions: Biological: cetuximab; Drug: dasatinib; Procedure: therapeutic conventional surgery
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck CancerCondition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: cisplatin; Radiation: intensity-modulated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Biological: cetuximab; Drug: 5-FU; Drug: oxaliplatin; Drug: leucovorin
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil; Procedure: computed tomography; Procedure: positron emission tomography; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Drug: Bevacizumab; Drug: Cetuximab; Drug: Pemetrexed; Radiation: Radiation therapy
Sponsors: University of Pittsburgh; University of Pittsburgh; Eli Lilly and Company; Genentech
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Intervention: Dietary Supplement: beta-glucan
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified June 2011 - Condition: Carcinoma, Squamous Cell
Intervention: Procedure: FDG-PET CT
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Carcinoma, Squamous Cell
Interventions: Drug: paclitaxel poliglumex; Biological: cetuximab; Radiation: radiation therapy (IMRT or 3D-CRT)
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Cell Therapeutics
Recruiting - verified April 2012 - Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Rectal Cancer
Interventions: Drug: Cetuximab; Drug: 5-Fluorouracil; Radiation: External Beam Pelvis Radiation Therapy
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Lung Cancer
Interventions: Biological: EGFRBi-armed autologous activated T cells; Biological: aldesleukin; Biological: sargramostim
Sponsors: Roger Williams Medical Center; Roger Williams Medical Center
Recruiting - verified January 2012 - Condition: Advanced Cancer
Interventions: Drug: Bevacizumab; Drug: Sorafenib; Drug: Erlotinib; Drug: Trastuzumab; Drug: Lapatinib; Drug: Sunitinib; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: 5-FU; Drug: Cetuximab; Drug: Dasatinib; Drug: Leucovorin; Drug: Oxaliplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: Metastatic Colorectal Cancer; EGFR-Expressing Metastatic CRC
Interventions: Drug: Sorafenib (Bay 43-9006); Biological: cetuximab; Genetic: proteomic profiling; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
 |
Cetuximab Clinical Trials |
